<b>Gapping up<br/>In reaction to strong earnings/guidance: </b>PLAY +9.7%, CONN +6.5%, RYAAY +4.7%, FCEL +4.2%, AGX +2.1%, TIVO +1.6%, HDS +1.5%, CASY +1.3%, KFY +0.9%, CLLS +0.5%<br/><br/><b>Select China related names showing strength:</b> JKS +5.3%, SOHU +3.2%, JD +2.9%, SFUN +2.7%, BABA +1.8%<br/><br/><b>Select metals/mining stocks trading higher: </b>AKS +4.5%, RIO +3.4%, VALE +3.2%, FCX +2.3%, BHP +1.0%<br/><br/><b>Other news: </b>AKBA +87.5% (announced positive top-line results from its Phase 2 study of vadadustat in dialysis patients with anemia related to chronic kidney disease), VTAE +30.4% (announced positive top-line results from initial phase 1 study of first-in-class RORyt Inhibitor VTP-43742 in autoimmune disorders), ACRX +18.1% (announces that ARX-04 met primary and secondary endpoints in a multi-center), BIOC +12.4% (allowance of U.S. Patent 9,128,082 entitled, devices and methods of cell capture and analysis), SBGL +10.2% (announces the proposed acquisition of the Rustenburg Operations from Anglo American Platinum Limited (AGPPY) for an upfront consideration of R1.5 bln), PLX +9.5% (announces positive interim data from its phase I/II clinical trial of 1mg/kg of PRX-102), NURO +9.1% (announced that the Quell Wearable Pain Relief Device is now commercially available on Amazon (AMZN)), PSTI +5.3% (concludes meeting with the FDA for filing an IND for PLX-R18; targets early 2016 to launch trial), BTU +4.4% (cont vol pre-mkt), SOHU +3.4% (rebounding modestly after recent sell off), DDD +1.9% (still checking), CLR +1.6% (announced plans to reduce its 2015 capital budget by $300-350 million more than previously approved), BDSI +1.4% (BioDelivery Sciences and Endo Pharma (ENDP) present new data on their investigational product, Buprenorphine HCl Buccal Film for chronic pain management), NFLX +1.1% (set to to launch in South Korea, Singapore, Hong Kong and Taiwan early next year), FB +1% (updates mobile features for Facebook Pages)<br/><br/><b>Analyst comments</b>: SUNE +2.7% (initiated with an Outperform at Oppenheimer), ETFC +2.6% (upgraded to Buy at Evercore ISI), ANTH +2.5% (initiated with a Buy at Sun Trust Rbsn Humphrey ), DPZ +2.1% (upgraded to Buy from Neutral at Goldman), GS +2% (upgraded to Buy from Neutral at BofA/Merrill), CSIQ +1.9% (initiated with an Outperform at Oppenheimer), FIT +1.9% (initiated with a Outperform at FBN Securities), TSLA +1.9% (initiated with Outperform at Oppenheimer; tgt $340), FSLR +1.8% (initiated with an Outperform at Oppenheimer), CELG +1.3% (initiated with a Buy at Jefferies), KPTI +1.3% (initiated with a Buy at Jefferies), ENLC +1.2% (upgraded to Buy at UBS), INTC +0.8% (initiated with a Buy at Sterne Agee CRT)<br/><br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance: </b>MW -5.3%, KLIC -5.3%, PBY -1.3%<br/><br/><b>Other news: </b>TTPH -79.2% (announced eravacycline did not achieve primary endpoint in pivotal portion of complicated urinary tract infections Trial), ZQK -79.1% (commences voluntary proceedings for relief under Chapter 11 of the United States Bankruptcy Code), FLXN -29.1% (reported top-line data from pivotal phase 2b clinical trial for FX006 in patients with moderate to severe osteoarthritis (OA) knee pain; primary endpoint of study not met), AQXP -13.1% (announced proposed public offering of $75 million of common stock), CMRX -5.2% (provided clinical development update for Brincidofovir, stating that SUPPRESS data continues to be expected in early 2016), FPRX -3.4% (initiated patient dosing in its Phase 1a/1b clinical trial, evaluating the immunotherapy combination of FPA008 with Opdivo), LNG -3.1% (Jim Chanos unveils new short position in LNG on CNBC), YHOO -1.9% (IRS determined not to grant Yahoo's request for a private letter ruling relating to the spin-off of its Alibaba (BABA) stake), UAL -0.9% (named Oscar Munoz as President and CEO; announced that its executive vice president of communications and government affairs and its senior vice president of corporate and government affairs have stepped down)<br/><br/><b>Analyst comments:</b> MNKD -8.6% (downgraded to Underweight from Neutral at Piper Jaffray), YGE -6.4% (downgraded to Sell at ROTH Capital; tgt $0.50), PII -1.4% (downgraded to Neutral from Buy at Longbow), THRX -1.3% (downgraded to Neutral from Buy at BofA/Merrill), TEX -0.7% (downgraded to Underweight from Neutral at JP Morgan ), CMA -0.6% (initiated with an Underperform at BMO Capital ), R -0.6% (downgraded to Sector Weight from Overweight at KeyBanc Capital Mkts)<br/><br/>Allikas: Briefing.com